Darmstadt, Germany — Merck, a leading company for innovative and

top-quality high-tech products in healthcare, life science and performance materials,

today announced that Andreas Stickler (43) has been appointed as new Head of

Controlling of the Healthcare Business Sector. Roman Morten Werth (38) will succeed

Andreas Stickler in his current position as Head of Mergers & Acquisitions (M&A). The

changes will take effect on Feb. 1, 2015.

“We’re delighted that two key positions in our Finance Function will be filled with

internal managers who bring the experience and the track record to ensure quality and

continuity alike,” said Marcus Kuhnert, Chief Financial Officer and Member of the

Executive Board of Merck.

In his new role, Andreas Stickler will be responsible for the controlling of the largest of

the three Business Sectors, which have been introduced on Jan. 1, 2015. In addition to

the biopharmaceutical business Merck Serono, the Business Sector Healthcare also

comprises the businesses Consumer Health, Biosimilars and Allergopharma. Andreas

Stickler has headed the M&A department since 2008 and in that role led major

transactions, including the takeover of Millipore (2010), AZ Electronic Materials (2014)

and the planned acquisition of Sigma Aldrich (announced 2014). He joined Merck in

2002, following positions at Degussa, Aventis and Hoechst. Roman Werth joined the

M&A department at Merck in 2008 and has played a key role in executing all major

M&A projects. Prior to his career at Merck, he had worked several years at M&A

departments of Siemens and Continental AG. In their new positions, Andreas Stickler

and Roman Werth will both report directly to Marcus Kuhnert.

Since 2004 Merck has invested around €18 billion in acquisitions and generated

around € 7 billion through divestments. The most recent transactions included the

€ 1.9 billion takeover of AZ Electronic Materials, a producer of high-tech electronic

materials for displays. In September 2014, Merck announced an agreement to acquire

Sigma-Aldrich for around € 13 billion to combine it with Merck Millipore and form one of

the leading life science companies globally. Both transactions have marked major

milestones in Merck’s “Fit for 2018” transformation and growth program aimed at

building three strong platforms for sustainable, profitable growth.